Merkel Cell Carcinoma Expresses Vasculogenic Mimicry: Demonstration in Patients and Experimental Manipulation in Xenografts

Citation
Lezcano, Cecilia, Sonja Kleffel, Nayoung Lee, Allison R. Larson, Qian Zhan, Andrew DoRosario, Linda C. Wang, Tobias Schatton, and George F. Murphy. 2014. “Merkel Cell Carcinoma Expresses Vasculogenic Mimicry: Demonstration in Patients and Experimental Manipulation in Xenografts.” Laboratory investigation; a journal of technical methods and pathology 94 (10): 1092-1102. doi:10.1038/labinvest.2014.99. http://dx.doi.org/10.1038/labinvest.2014.99.

Published Version
doi:10.1038/labinvest.2014.99

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:15034897

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Merkel Cell Carcinoma Expresses Vasculogenic Mimicry: Demonstration in Patients and Experimental Manipulation in Xenografts

Cecilia Lezcano1, Sonja Kleffel2,3, Nayoung Lee2,3, Allison R. Larson2,3, Qian Zhan3,4, Andrew DoRosario3,5, Linda C. Wang6, Tobias Schatton2,3,7, and George F. Murphy3,4

1Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA
2Department of Dermatology, Brigham and Women’s Hospital, Boston, MA
3Harvard Medical School, Boston, MA
4Department of Pathology, Brigham and Women’s Hospital, Boston, MA
5Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA
6Institute for Cancer Care, Mercy Medical Center, Baltimore, MD
7Transplantation Research Center, Children’s Hospital Boston, MA

Abstract

Merkel cell carcinoma (MCC) is a highly virulent cutaneous neoplasm that, like melanoma, is a frequent cause of patient morbidity and mortality. The cellular mechanisms responsible for the aggressive behavior of MCC remain unknown. Vasculogenic mimicry (VM) is a phenomenon associated with cancer virulence, including in melanoma, whereby anastomosing laminin networks form in association with tumor cells that express certain endothelial genes. To determine whether VM is a factor in MCC, we employed a relevant xenograft model using two independent human MCC lines. Experimentally induced tumors were remarkably similar histologically to patient MCC, and both contained laminin networks associated with vascular endothelial-cadherin (CD144) and vascular endothelial growth factor receptor 1 (VEGFR-1) as well as Nodal expression typical of VM in melanoma. Moreover, two established chemotherapeutic agents utilized for human MCC, etoposide and carboplatin, induced necrosis in xenografts upon systemic administration while enriching for laminin networks in apparently resistant viable tumor regions that persisted. These findings for the first time establish VM-like laminin networks as a biomarker in MCC, demonstrate the experimental utility of the MCC xenograft model, and suggest that VM-rich regions of MCC may be refractory to conventional chemotherapeutic agents.

Corresponding Author: George F. Murphy, M.D., 221 Longwood Avenue, EBRC 401, Boston, MA 02115, Tel: 617--525-7485; fax: 617-264-5149, gmurphy@rics.bwh.harvard.edu.

Disclosures/Duality of Interest
The authors have no conflicts of interest to disclose.
Keywords
laminin; Merkel cell carcinoma; vasculogenic mimicry; vasculogenic plasticity

Merkel cell carcinoma (MCC) is a rare and highly aggressive cutaneous neoplasm with a high rate of morbidity and mortality.\[1, 2\] The mechanisms underlying MCC aggressiveness have not been fully characterized. However, like melanoma, MCC was found to express virulence-conferring factors, such as the embryonic neural crest stem cell transcription factor, SOX2, which is associated with invasiveness and tumorigensis in melanoma.\[3\] An additional biomarker and potential mechanism associated with tumor aggressiveness is vasculogenic mimicry (VM) whereby anastomosing periodic acid-Schiff (PAS)- and laminin-positive networks develop within tumors.\[4, 5\] In melanoma, vascular endothelial growth factor receptor 1 (VEGFR1)\(^+\) tumor subsets drive tumor growth and form patterned networks with structural and antigenic characteristics of VM. Indeed, pioneering work by Hendrix, Folberg, and others have shown these laminin networks to be associated with melanoma virulence by forming channels that facilitate perfusion via direct or indirect connections with authentic vessels.\[6, 7\] Whereas tumor angiogenesis involves ingrowth and sprouting of stromal vessels lined by platelet endothelial cell adhesion molecule 1 (CD31)-expressing endothelial cells,\[8–10\] VM networks are intimately associated with tumor cells that express endothelial genes encoding for vascular endothelial-cadherin (CD144), TIE-1, and VEGFR-1, but not CD31.\[5, 6, 11, 12\] In this study we aimed to assess whether MCC similarly harnesses VM to propagate tumor aggressiveness. Using patient biopsies and a xenograft model relevant to human disease, here we show that VM may be documented clinically and experimentally manipulated in MCC, establishing VM as a novel biomarker for this important tumor type.

Materials and Methods

Cell Lines and Cell Culture

Authenticated human Merkel cell carcinoma cell lines (MKL-1 and WaGa) were obtained courtesy of Dr. James DeCaprio at the Dana-Farber Cancer Institute, Boston, MA\[13\] and were cultured fewer than 6 months in RPMI 1640 medium supplemented with 20% (v/v) FBS and 1% (v/v) penicillin/streptomycin (Gibco, Life Technologies, Grand Island, NY). Authenticated human umbilical vein endothelial cells (HUVEC) were obtained from the American Type Culture Collection (ATCC) and cultured in M199 medium supplemented with 10% (v/v) FBS, 1% (v/v) penicillin/streptomycin (Gibco, Life Technologies), 100µg/ml (wt/v) endothelial cell growth supplement (Biomedical Technologies, Ward Hill, MA), 100µg/ml (wt/v) heparin, 100nM (v/v) hydrocortisone and 100nM (v/v) ascorbic acid in fibronectin-coated (20µg/ml) flasks (Sigma-Aldrich, St. Louis, MO).

Generation of drug-resistant MCC lines

MKL-1 and WaGa cells were incubated in growth media as above supplemented with weekly increasing doses of carboplatin (\(\leq 50\ \mu\text{M},\) Sigma) or etoposide (\(\leq 5\ \mu\text{M},\) Sigma) over the course of 2 months. CD144, LAMA3, LAMB3 and LAMC2 mRNA expression was quantified as described below.

Lab Invest. Author manuscript; available in PMC 2015 April 01.
RNA extraction, reverse transcription and real-time quantitative PCR

Total RNA was isolated from vehicle-treated, carboplatin- or etoposide-resistant MKL-1 and WaGa cells, and human umbilical vein endothelial cells using the RNeasy Plus Mini Kit (Qiagen, Venlo, Limburg). Standard cDNA synthesis reactions were carried out using the SuperScript VILO cDNA synthesis kit (Invitrogen, Life Technologies) and reverse transcribed products were amplified with the Fast SYBR Green Master Mix (Applied Biosystems, Life Technologies) according to the manufacturer’s instructions. The primers for detection of human CD144 by real-time quantitative RT-PCR were: 5’-CAGCCCAAAGTGTGTGAGAA-3’ (forward) and 5’-CGGTCAAACTGCCCATACTT-3’ (reverse), for human LAMA3 detection: 5’-ATCTG GAGTCGAAGTCCGACTG -3’ (forward) and 5’-TTGTAGACACAGGTGAGCTGC-3’ (reverse), for human LAMB3 detection: 5’-ACCACACCGAAGGCAAGAAC-3’ (forward) and 5’-GGTTGGCGTAGGTAGTCCA-3’ (reverse), for human LAMC2 detection: 5’-AGGCTGTCCAACGAAATGGG-3’ (forward) and 5’-GGAGCTGTGATCCGTAGACCA-3’ (reverse), for human 18S rRNA detection: 5’-GGTTGGCGTAGGTAGTCCA-3’ (forward) and 5’-GCGTGGATTCTGATCATATGGT -3’ (reverse). Kinetic PCR was performed on a StepOne Plus Real-Time PCR System (Applied Biosystems). All samples were run in triplicate. The relative amounts of PD-1 transcripts were analyzed by the 2(−ΔΔCt) method as described previously.[14]

Animals

Non-obese diabetic/severe combined immunodeficiency (NOD/SCID) interleukin (IL)-2 Rg−/− knockout (NSG) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were maintained in accordance with the institutional guidelines of Harvard Medical School and experiments were performed according to approved experimental protocols.

Human MCC Xenotransplantation and Carboplatin and Etoposide Treatment

For tumorigenicity studies, MKL-1 or WaGa MCC cells were injected subcutaneously into the bilateral flanks of recipient NSG mice (1 × 10^7/injection) as described.[15] Tumorigenic growth was assayed after 6 weeks of growth, unless protocol-stipulated euthanasia necessitated sacrifice prior to this, in situations of excessive tumor growth or animal morbidity. At day 34 post tumor cell inoculation, mice were randomized to carboplatin, etoposide or vehicle control treatment groups with similar tumor volumes. Carboplatin (Novaplus, Lake Forest, IL) or etoposide (APP pharmaceuticals, Schaumburg, IL) was administered daily by intraperitoneal injection for 6 consecutive days, at 75 mg/kg or 10 mg/kg body weight, respectively, and control animals were given vehicle only, PBS, at equal volumes as previously described.[16] Tumor volumes were measured daily for the duration of the treatment, xenografts harvested 1 day following administration of the final treatment dose, and frozen or paraffin-embedded MCC sections were prepared for subsequent immunohistochemical analysis.
Human MCC Samples

According to IRB approved protocols, 7 clinically-annotated formalin-fixed paraffin-embedded (FFPE) specimens of MCC were obtained from six patients; 4 of them were cutaneous lesions (of which two were primary lesions and 2 were recurrent cutaneous lesions), and 3 were lymph node metastases. The two specimens that corresponded to cutaneous recurrences were obtained after the patients were treated with at least one cycle of the combination of carboplatin and etoposide.

Histochemistry, Immunohistochemistry (IHC) and Immunofluorescence (IF)

All patient MCCs (n=7) and xenografts (n=41; 6 WaGa vehicle, 7 MKL-1 vehicle, 8 WaGa etoposide, 8 WaGa carboplatin, 6 MKL-1 etoposide, 6 MKL-1 carboplatin) were stained with hematoxylin and eosin (H&E). Biomarkers of proven relevance in the detection of vasculogenic mimicry were selected (Table 1) and employed for IHC. All patient specimens and selected xenografts (n=18; 3 WaGa vehicle, 3 MKL-1 vehicle, 3 WaGa etoposide, 3 WaGa carboplatin, 3 MKL-1 etoposide, 3 MKL-1 carboplatin) were stained for periodic acid-Schiff (PAS), laminin (Dako, Carpinteria, CA), Ulex europaeus-I (Sigma-Aldrich), and human or mouse CD31 (Bethyl Laboratories, Montgomery, TX and Abcam, Cambridge, MA, respectively; used on human MCC and xenograft sections, respectively) in FFPE tissue. None of the anti-CD31 antibodies employed is species specific, and human-mouse cross-reactivity was anticipated and encountered. FFPE patient tissue (n=4) was also stained for CD144 (Cell Signaling, Danvers, MA). FFPE samples were deparaffinized and epitope retrieval was achieved by enzymatic digestion with proteinase K (New England BioLabs, Ipswich, MA) for laminin detection or by heating tissue sections in sodium citrate solution (pH 6.0) (Dako) for human and mouse CD31 as well as for CD144. Frozen sections from xenografts (n=6; 1 WaGa vehicle, 1 MKL-1 vehicle, 1 WaGa etoposide, 1 WaGa carboplatin, 1 MKL-1 etoposide, 1 MKL-1 carboplatin) were utilized for CD144 (Cell Signaling), Nodal (Abnova, Golden, CO) and VEGFR-1 (R&D Systems, Minneapolis, MN) IHC. All sections were incubated overnight with primary antibodies at room temperature (~25°C) followed by 2-hour incubation with HRP-conjugated goat anti-rabbit (for Ulex, human and mouse CD31, CD144 and laminin), horse anti-goat (for VEGFR-1) and horse anti-mouse (for Nodal) secondary antibodies (all Vector Laboratories, Burlingame, CA) at room temperature. HRP-substrate NovaRed (Vector Laboratories) was used for immunoreactivity detection. Double labeling for human CD31 (AbD Serotec, Kidlington, UK)-CD144 (Cell Signaling) was performed as described above, incubating a tissue sample with Alexa Fluor® 488 and 594 goat anti-mouse and goat anti-rabbit secondary antibodies (Invitrogen), respectively. Double labeling for laminin and associated VM markers was not utilized, as the former requires proteinase K digestion that abrogates bioreactivity for the second epitopes. Adjacent sections were used for comparative purposes of single epitope expression to minimize likelihood of variation based in section depth (all sections were 4–6 microns thick).

Additionally lungs from 20 mice (3 WaGa vehicle, 3 MKL-1 vehicle, 4 WaGa etoposide, 4 WaGa carboplatin, 3 MKL-1 etoposide, 3 MKL-1 carboplatin) were stained for H&E and CK20 (Dako) to evaluate presence of MCC metastases in random sections.
Quantitative Assessment of IHC in MCC Xenografts

Viable areas in the periphery of xenografted tumors (n=18; 3 WaGa vehicle, 3 MKL-1 vehicle, 3 WaGa etoposide, 3 WaGa carboplatin, 3 MKL-1 etoposide, 3 MKL-1 carboplatin) with similar density of CD31+ vessels were sampled (two high-power 400× fields per specimen) for computer-assisted quantitative evaluation of laminin+ structures consistent with vasculogenic mimicry. Additionally, tumor micronodules within networks defined by CD144, Nodal and VEGFR-1 in xenografted tumors (n=6; 1 WaGa vehicle, 1 MKL-1 vehicle, 1 WaGa etoposide, 1 WaGa carboplatin, 1 MKL-1 etoposide, 1 MKL-1 carboplatin) were evaluated (one 1000× field) for maximal size measuring their greatest dimension.

Xenografted tumors (n=18; 3 WaGa vehicle, 3 MKL-1 vehicle, 3 WaGa etoposide, 3 WaGa carboplatin, 3 MKL-1 etoposide, 3 MKL-1 carboplatin) and patient MCCs (n=7) were evaluated for angiogenesis by counting the number of CD31+ vessels at low magnification (100×). Photomicrographs were taken using a Nikon Elipse 80i microscope coupled with a SPOT Insight 4.0 Mp Firewire Color Mosaic (model 14.2) camera and then analyzed employing Image J software (NIH, Bethesda, MD) for all quantitative assessments.

Statistical Analysis

Two-sided t-tests were used for all comparisons. A p-value of less than 0.05 was considered significant. Data are reported as sample means with error bars representing the standard error of the means.

Results

Histology of WaGa and MKL-1 derived MCC xenografts

WaGa and MKL-1 cells subcutaneously injected to NSG mice both gave rise to nodular tumors composed of uniform populations of small basophilic cells with high nuclear to cytoplasmic ratios (Figure 1). The nuclei were rounded and the chromatin showed the classic finely granular, stippled appearance typical of MCC. MKL-1 tumor cells were slightly larger than WaGa cells, and MKL-1-derived tumors displayed trabecular architecture while WaGa tumors grew as sheets of cells. Tumors showed a destructive relationship to subcutaneous structures, with permeation through the panniculus carnosus muscular layer. Lymphovascular invasion was not prominent, and pulmonary micrometastasis was documented in random sections in only one of 20 animals with up to 6 weeks of primary xenograft growth. Immunohistochemically, MCC xenografts showed CK20-positivity in a dot-like perinuclear pattern identical to that seen in patient tumors.

CD31+ and Ulex+ murine vessels were present in relatively low density throughout tumor nodules (average of 13 cross-sectional CD31+ vessel profiles per 100× field [range of 8 to 20]; n=18) (Figure 2). In comparison, laminin and PAS stains in adjacent sections revealed in all 18 xenografts evaluated elaborate, branching and anastomosing networks that were in large part not spatially coincident with either CD31+ or Ulex+ vessels, and accounted for >90% of laminin staining. Further biomarker analysis of these networks revealed coincident staining patterns for the endothelial-associated marker CD144 (VE-cadherin), the vascular endothelial growth factor receptor 1 (VEGFR-1), and the embryonic morphogen, Nodal, all previously associated with the phenomenon of VM in melanoma,[5, 6, 12, 17] in
representative xenografts derived from both cell lines and corresponding to each of the 3
treatment groups (n=6). Micronodules of tumor compartmentalized by the networks defined
by all of the above biomarkers (excluding CD31 and Ulex) showed a consistent maximum
diameter of 40 to 50 µm, and thus the pattern of immunoreactivity for all markers
corresponded both qualitatively and quantitatively.

**Effect of chemotherapy on WaGa and MKL-1 tumors**

In view of the established chemotherapy resistance of cells known to be associated with
VM, [5, 18] we next addressed WaGa and MKL-1-derived tumors harvested after systemic
administration of the chemotherapeutic agents etoposide, a topoisomerase II inhibitor; or
carboplatin, an alkylating-like platinum-based drug. Animals so treated exhibited xenograft
tumors with centrally localized zones of prominent tumor necrosis that were not present in
vehicle-treated xenografts. PAS and laminin stains showed qualitative increase over baseline
in anastomosing networks in residual viable regions of tumor of both WaGa and MKL-1-
derived xenograft tumors after both modalities of chemotherapy. This increase was further
confirmed by quantification of laminin positivity in tumor areas matched for density of
CD31+ vessels (Figure 3 upper and middle panels). There was a statistically significant
increase in laminin+ network immunoreactivity per unit area in viable tumor areas of both
MKL-1 and WaGa tumors after carboplatin, and also after etoposide in MKL-1 tumors,
when compared to vehicle-treated xenografts. WaGa tumors treated with etoposide showed
a trend in the same direction, although it did not reach statistical significance (Figure 3,
graphs). CD144 retained a network pattern similar to that described for vehicle-treated
xenografts, and qualitatively also was increased in evaluable specimens that showed
augmentation in laminin networks. Quantitative analyses for other biomarkers were not
performed in tissue sections obtained after chemotherapy due to technical limitations related
to the extent of tumor necrosis in the samples that were allocated for frozen sectioning.

In order to assess further the changes after chemotherapy administration observed in vivo,
we employed etoposide and carboplatin-resistant WaGa and MKL-1 cells to compare the
levels of expression of three laminin isoforms and CD144 by real-time quantitative RT-PCR
against those found in vehicle-treated WaGa and MKL-1 cells (Figure 4). We found that
both etoposide and carboplatin-resistant WaGa and MKL-1 cells showed statistically
significant increases in mRNA levels for two of the three laminin isoforms tested (LAMA3
and LAMC2), while only etoposide-resistant MKL-1 cells showed significantly augmented
levels for the remaining laminin isoform (LAMB3). Additionally, CD144 expression also
was increased in etoposide and carboplatin resistant cell lines compared to vehicle-treated
controls, although statistical significance was reached only in carboplatin resistant WaGa
cells (Figure 4).

**Patient MCC**

Seven MCC specimens from 6 patients were evaluated for presence of anastomosing
networks similar to those observed in MCC xenografts. Four of them showed similar,
although less elaborate and dense, linear branching structures on PAS stain (Table 2); these
were present diffusely throughout the tumor in one case, and distributed more focally in the
remaining 3 cases. Serial sections demonstrated identical patterns by laminin
immunohistochemistry for each of these 4 cases. Although CD31+ vessels in patient tumors were more abundant than in xenografts (average 30 cross-sectional CD31+ vessel profiles [range of 21 to 42]; n=7), they spatially coincided with only a fraction of the networks defined by laminin immunoreactivity in the four positive cases (Figure 5, upper and middle panels). Immunoreactivity for Ulex europaeus further confirmed the pattern of endothelial distribution detected by CD31 (data not shown). Computer-assisted image analysis of sequential sections from one of these specimens confirmed that CD31 staining was associated with 20% of the intratumoral networks defined by laminin immunohistochemistry. Additionally, immunofluorescence dual labeling established these networks to be associated with positivity for CD144 but not for CD31. Interposed tumor vessels were positive for both epitopes. (Figure 5, bottom panels). Taking all 7 human MCC specimens as a group, no clear associations between presence or extent VM and presumed lesion aggressiveness (i.e. primary vs. recurrence vs. metastasis) or chemotherapy treatment status were observed (Table 2).

Discussion

Vasculogenic mimicry (VM) is a mechanism intrinsic to a number of human cancers that is associated with aggressive behavior. Among skin cancers, melanoma and Merkel cell carcinoma (MCC) are the most virulent, and VM is a well-recognized phenomenon in melanoma. We thus posited that VM may play a similar role in MCC. Because it has been found that VM is a more readily and consistently demonstrable phenomenon in conditions associated with intratumoral hypoxia, such as may occur in aggressive, rapidly growing tumors with high metabolic demands, we first employed a MCC xenograft model for experimental identification and manipulation of VM that, like melanoma xenografts, exhibited accelerated growth rates as compared to patient tumors. Using two distinct human MCC lines, xenograft tumors remarkably similar to primary MCC in humans were generated. Initial PAS and laminin staining of these tumors revealed complex anastomosing and branching networks diffusely throughout tumor nodules. Importantly, the majority (>90%) of these laminin-positive structures were unassociated with CD31 reactivity, thus exempting them from basement membranes integral to conventionally-induced tumor angiogenesis. Regardless of CD31 negativity, laminin within tumors need not imply VM. We therefore utilized a panel of biomarkers associated with VM to further confirm our findings. These included CD144 (VE-cadherin), a marker associated with endothelial lineage and previously shown to be characteristic of CD31+ tumor cells associated with laminin network formation; VEGFR-1 a receptor involved in tumor angiogenesis and recently shown to promote and regulate laminin network formation in melanoma; and Nodal, an embryonic morphogen previously identified in association with VM both in experimental melanomas and patient tumors. These biomarkers further confirmed the presence of VM in MCC xenografts.

VM was originally considered by Hendrix and co-workers to be produced by less differentiated populations of cancer cells capable of phenotypic and functional plasticity, and this insight is fortified by the association of melanoma subpopulations of established chemoresistance with laminin network formation regulated by the VEGFR-1 pathway. Because such subpopulations are notoriously resistant to chemotherapy and might be...
enriched in tumors as a consequence of chemotherapy,[4, 37, 38] we hypothesized that VM driven by melanoma subpopulations[5, 39] may also be similarly protected or augmented in MCC. Indeed, our study indicates that laminin networks are enhanced in xenografts derived from two separate MCC lines in response to two different chemotherapeutic agents of established clinical relevance to the treatment of patient MCC, etoposide and carboplatin. Furthermore, we performed in vitro assays in the absence of endothelial cells that produce laminin in tumor xenografts or patient samples, and were able to demonstrate increased mRNA levels for three laminin isoforms and CD144 in etoposide and carboplatin-resistant WaGa and MKL-1 cells compared to vehicle-treated counterparts. Although not all measurements were statistically significant, a trend consistent with enhanced VM was observed. These results support the notion that chemoresistance induces a VM-like phenotype in MCC lines in vitro. In spite of the limited numbers of samples evaluated in this study, taken together these results suggest that MCC subpopulations capable of VM may have a survival advantage in certain therapeutic settings.

Although laminin networks are also detected in MCC from patients, they are not as well developed or elaborately expressed as in xenograft tumors. This difference could be related to differences in growth rates between naturally occurring and xenograft tumors. This potentially has at least two interrelated consequences: 1) robust tumor expansion in xenografts may outstrip the ability of stromal-derived murine angiogenesis to populate the growing nodule with authentic tumor vessels,[36] and 2) resultant production of a hypoxic, metabolically stressed microenvironment may drive VM.[35] Indeed, CD31+ vessels are considerably fewer in xenografts than in patient tumors that generally have gradual growth over many months to years, a finding that supports this hypothesis. In 1986, Hall et al. reported that human primary and secondary Merkel cell carcinomas (n=9) showed no detectable laminin immunoreactivity except for that associated with small vessels and epidermal basement membranes.[40] Merkel cell carcinomas are recognized to be vascularized tumors capable of expressing angiogenic factors that promote their growth and for which targeted anti-angiogenic drugs have been proposed as a therapeutic strategy.[41] Thus it is possible that intratumoral laminin immunoreactivity could have been entirely attributed to conventional angiogenesis, emphasizing the potential difficulty in recognizing VM networks without additional markers to prove the absence of endothelium. Alternatively, it is possible that differences in sensitivity of laminin detection are responsible for the conclusion in the Hall study.

Whether VM in MCC is involved solely in nutrient perfusion via laminin-lined sinusoidal conduits that accommodate extravasated blood from leaky tumor vessels, as has been posited,[6] remains unknown. An intriguing possibility is that VM may additionally provide a 3-dimensional stimulatory scaffold that supports tumorigenic expansion of proliferating neoplastic cells. The recognized role of laminin as a cancer cell mitogen,[42, 43] as well as the propensity for cancer growth to exhibit stromal/extracellular matrix dependency,[44–46] offer potential support to this theory. The establishment of VM in MCC evaluable in a xenograft model relevant to human disease now provides a pathway for additional research into these and other issues relating to elucidation of mechanisms of MCC virulence. In the present study, the results on a limited number of human specimens did not show a clear
association between presence or extent of VM and lesion aggressiveness or response to chemotherapy. However, assessment of a larger cohort of annotated patient biospecimens will be necessary to determine whether VM is an informative biomarker for prognosis, staging, and determination of therapeutic resistance in MCC. Nonetheless, the establishment of VM in MCC, and data indicating its resistance to conventional chemotherapy, provide new insights into underlying pathways for tumor virulence that now may be further explored mechanistically.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgments**

NIH-P50 CA93683 and R01 CA58467 (G.F.M.) and Brigham and Women’s Hospital Department of Dermatology Funding for Young Investigators (T.S.) supported the present work. T.S. is the recipient of a Research Career Development Award from the Dermatology Foundation.

**Abbreviations**

- **CD31**: cluster of differentiation 31/platelet endothelial cell adhesion molecule 1
- **CD144**: cluster of differentiation 144/vascular endothelial-cadherin
- **CK20**: cytokeratin 20
- **FFPE**: formalin-fixed paraffin-embedded
- **H&E**: hematoxylin and eosin
- **HRP**: horseradish-peroxidase
- **IF**: immunofluorescence
- **IHC**: immunohistochemistry
- **MCC**: Merkel cell carcinoma
- **PAS**: periodic acid-Schiff
- **SOX2**: SRY (sex determining region Y)-box 2
- **TIE-1**: tyrosine kinase with immunoglobulin-like and EGF-like domains 1
- **VEGFR-1**: vascular endothelial growth factor receptor 1
- **VM**: vasculogenic mimicry

**References**

1. Akhtar S, Oza KK, Wright J. Merkel cell carcinoma: report of 10 cases and review of the literature. J Am Acad Dermatol. 2000; 43:755–767. [PubMed: 11050578]
2. Yiengpruksawan A, Coit DG, Thaler HT, et al. Merkel cell carcinoma. Prognosis and management. Arch Surg. 1991; 126:1514–1519. [PubMed: 1842182]
3. Laga AC, Lai CY, Zhan Q, et al. Expression of the embryonic stem cell transcription factor SOX2 in human skin: relevance to melanocyte and merkel cell biology. Am J Pathol. 2010; 176:903–913. [PubMed: 20042675]
4. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature. 2008; 451:345–349. [PubMed: 18202660]
5. Frank NY, Schatton T, Kim S, et al. VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res. 2011; 71:1474–1485. [PubMed: 21212411]
6. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999; 155:739–752. [PubMed: 10487832]
7. Seftor EA, Meltzer PS, Kirschmann DA, et al. Molecular determinants of human uveal melanoma invasion and metastasis. Clin Exp Metastasis. 2002; 19:233–246. [PubMed: 12067204]
8. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285:1182–1186. [PubMed: 4938153]
9. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86:353–364. [PubMed: 8756718]
10. Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell. 1998; 94:715–725. [PubMed: 9753319]
11. Bissell MJ. Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name? Am J Pathol. 1999; 155:675–679. [PubMed: 10487823]
12. Hendrix MJ, Seftor EA, Meltzer PS, et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci U S A. 2001; 98:8018–8023. [PubMed: 11416160]
13. Rodig SJ, Cheng J, Wardzala J, et al. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest. 2012; 122:4645–4653. [PubMed: 2314601]
14. Frank NY, Margaryan A, Huang Y, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005; 65:4320–4333. [PubMed: 15899824]
15. Lian CG, Xu Y, Ceol C, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell. 2012; 150:1135–1146. [PubMed: 22980977]
16. Fichtner I, Rolff J, Soong R, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 2008; 14:6456–6464. [PubMed: 18927285]
17. McAllister JC, Zhan Q, Weishaupt C, et al. The embryonic morphogen, Nodal, is associated with channel-like structures in human malignant melanoma xenografts. J Cutan Pathol. 2010; 37(Suppl 1):19–25. [PubMed: 20482672]
18. Wilson BJ, Schatton T, Zhan Q, et al. ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res. 2011; 71:5307–5316. [PubMed: 21652540]
19. Shirakawa K, Kobayashi H, Heike Y, et al. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res. 2002; 62:560–566. [PubMed: 11809710]
20. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010; 468:829–833. [PubMed: 21102433]
21. Sun B, Zhang S, Zhao X, et al. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. Int J Oncol. 2004; 25:1609–1614. [PubMed: 15547697]
22. Hendrix MJ, Seftor EA, Kirschmann DA, et al. Molecular biology of breast cancer metastasis. Molecular expression of vascular markers by aggressive breast cancer cells. Breast Cancer Res. 2000; 2:417–422. [PubMed: 11250735]
23. Liu R, Yang K, Meng C, et al. Vasculogenic mimicry is a marker of poor prognosis in prostate cancer. Cancer Biol Ther. 2012; 13:527–533. [PubMed: 22407030]
24. Chai DM, Bao QZ, Hu JG, et al. Vasculogenic mimicry and aberrant expression of HIF-1alpha/E-cad are associated with worse prognosis of esophageal squamous cell carcinoma. J Huazhong Univ Sci Technolog Med Sci. 2013; 33:385–391. [PubMed: 23771665]
25. Lu XS, Sun W, Ge CY, et al. Contribution of the PI3K/MMPs/Ln-5gamma2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas. Int J Oncol. 2013; 42:2103–2115. [PubMed: 23588386]
26. Wang SY, Ke YQ, Lu GH, et al. Vasculogenic mimicry is a prognostic factor for postoperative survival in patients with glioblastoma. J Neurooncol. 2013; 112:339–345. [PubMed: 23417321]

27. Yu L, Wu SW, Zhou L, et al. Correlation between bacterial L-form infection, expression of HiF-1alpha/MMP-9 and vasculogenic mimicry in epithelial ovarian cancer. Sheng Li Xue Bao. 2012; 64:657–665. [PubMed: 23258329]

28. Wu S, Yu L, Wang D, et al. Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry. BMC Cancer. 2012; 12:535. [PubMed: 23170850]

29. Lin P, Wang W, Sun BC, et al. Vasculogenic mimicry is a key prognostic factor for laryngeal squamous cell carcinoma: a new pattern of blood supply. Chin Med J (Engl). 2012; 125:3445–3449. [PubMed: 23044304]

30. Sun W, Shen ZY, Zhang H, et al. Overexpression of Hi-1alpha in primary gallbladder carcinoma and its relation to vasculogenic mimicry and unfavourable prognosis. Oncol Rep. 2012; 27:1990–2002. [PubMed: 22470047]

31. Wang SY, Yu L, Ling GQ, et al. Vasculogenic mimicry and its clinical significance in medulloblastoma. Cancer Biol Ther. 2012; 13:341–348. [PubMed: 22258034]

32. Baeten CI, Hillen F, Pauwels P, et al. Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum. 2009; 52:2028–2035. [PubMed: 19934926]

33. van Beurden A, Schmitz RF, van Dijk CM, et al. Periodic acid Schiff loops and blood lakes associated with metastasis in cutaneous melanoma. Melanoma Res. 2012; 22:424–429. [PubMed: 23010821]

34. Kirschmann DA, Seftor EA, Hardy KM, et al. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res. 2012; 18:2726–2732. [PubMed: 22474319]

35. Sun B, Zhang D, Zhang S, et al. Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett. 2007; 249:188–197. [PubMed: 16997457]

36. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989; 49:6449–6465. [PubMed: 2684393]

37. Chartrain M, Riond J, Stennevin A, et al. Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. PLoS One. 2012; 7:e36762. [PubMed: 22675422]

38. Cheung ST, Cheung PF, Cheng CK, et al. Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology. 2011; 140:344–355. [PubMed: 20682318]

39. Chiao MT, Yang YC, Cheng WY, et al. CD133+ glioblastoma stem-like cells induce vascular mimicry in vivo. Curr Neurovasc Res. 2011; 8:210–219. [PubMed: 21675958]

40. Hall PA, d'Ardenne AJ, Butler MG, et al. Cytokeratin and laminin immunostaining in the diagnosis of cutaneous neuro-endocrine (Merkel cell) tumours. Histopathology. 1986; 10:1179–1190. [PubMed: 2433207]

41. Kukko H, Kojonen V, Lassus P, et al. Expression of vascular endothelial growth factor receptor-2 in Merkel cell carcinoma. Anticancer Res. 2007; 27:2587–2589. [PubMed: 17695419]

42. Mortarini R, Gismondi A, Maggioni A, et al. Mitogenic activity of laminin on human melanoma and melanocytes: different signal requirements and role of beta 1 integrins. Cancer Res. 1995; 55:4702–4710. [PubMed: 7553652]

43. Panayotou G, End P, Aumailley M, et al. Domains of laminin with growth-factor activity. Cell. 1989; 56:93–101. [PubMed: 2491959]

44. Bremnes RM, Donnem T, Al-Saad S, et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol. 2011; 6:209–217. [PubMed: 21107292]

45. Pouliot N, Kusuma N. Laminin-511: a multi-functional adhesion protein regulating cell migration, tumor invasion and metastasis. Cell Adh Migr. 2013; 7:142–149. [PubMed: 23076212]

46. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012; 196:395–406. [PubMed: 22351925]
47. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol. 2000; 156:361–381. [PubMed: 10666364]

48. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 2006; 39:469–478. [PubMed: 17002866]

49. Vartanian A, Stepanova E, Grigorieva I, et al. VEGFR1 and PKCalpha signaling control melanoma vasculogenic mimicry in a VEGFR2 kinase-independent manner. Melanoma Res. 2011; 21:91–98. [PubMed: 21389833]

50. Hendrix MJ, Seftor EA, Seftor RE, et al. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer. 2007; 7:246–255. [PubMed: 17384580]

51. Seftor RE, Seftor EA, Koshikawa N, et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res. 2001; 61:6322–6327. [PubMed: 11522618]

52. Simon-Assmann P, Orend G, Mammadova-Bach E, et al. Role of laminins in physiological and pathological angiogenesis. Int J Dev Biol. 2011; 55:455–465. [PubMed: 21858771]
**Figure 1. MCC xenograft model**

NSG mice injected with human MCC lines (WaGa, top panels; MKL-1, bottom panels) developed visible tumor masses (encircled in dotted lines) within a month (left panels; original magnification, 1×) of tumor cell xenografting. Tumors involved the dermis and subcutaneous tissue and were composed of uniform, small basophilic cells (center panels; original magnification, 100×). The classic salt and pepper chromatin pattern was observed within rounded nuclei rimmed by scant cytoplasm that showed dot-like positivity for CK20 (right panels; original magnification 1000×).
Figure 2. VM in MCC xenografts
WaGa and MKL-1-derived xenograft tumors contained CD31− anastomosing networks that were enhanced with PAS staining, and were associated with staining for laminin (Lam), CD144, Nodal and VEGFR-1. Note the density and complexity of laminin+ structures in comparison to CD31+ vessels (CD31 and Lam panels original magnification, 200×; PAS, CD144, Nodal, and VEGFR-1 original magnification, 1000×).
Figure 3. VM in MCC xenografts after chemotherapy
MKL-1 tumors treated with vehicle, carboplatin and etoposide stained for CD31 (upper panels; original magnification, 100×) and laminin (Lam) (middle panels; original magnification, 100×); rectangular regions are representative fields enlarged for clarity (original magnification, 1000×). Note the marked and widespread increase in laminin+ networks after chemotherapy. A similar picture is observed in WaGa derived tumors, although less diffusely (data not shown). A statistically significant increase in laminin...
immunoreactivity after carboplatin is observed in both cell lines, and after etoposide in MKL-1 derived tumors (graphs, lower panels).
Figure 4. Expression of VM-associated markers by carboplatin- and etoposide-resistant MCC cells
Relative LAMA3 (left), LAMB3 (center, left), LAMC2 (center, right) and CD144 (right) mRNA expression (mean ± s.e.m.) by carboplatin- and etoposide-resistant versus vehicle-treated MKL-1 (top) and WaGa (bottom) cells, as determined by real-time quantitative RT-PCR. Established human umbilical vein endothelial cells (HUVEC) served as a positive control. Data are representative of n=3 independent experiments. *P<0.05, **P<0.01, ***P<0.001.*
Figure 5. VM in patient MCC
PAS-positive networks also are demonstrable by laminin IHC, and a minority of these are associated with CD31 staining in adjacent sections original magnification, 100×; inset, 1000×). Double IF labeling for CD31 and CD144 demonstrates an architectural pattern of CD144 positivity similar to that seen with laminin, and distinct from the comparatively few and discrete CD31⁺ vessels (original magnification, 200×)
Table 1

Biomarkers employed for identification of VM versus true angiogenesis.

| Marker | VM          | Angiogenesis | Reference                                      |
|--------|-------------|--------------|------------------------------------------------|
| CD31   | -           | endothelium  | Hendrix M.J. et al.[12]                        |
|        |             |              | Folberg R. et al.[47]                         |
| CD144  | tumor cells | endothelium  | Hendrix M.J. et al.[12]                        |
|        |             |              | Frank N.Y. et al.[5]                          |
| VEGFR-1| tumor cells | endothelium  | Shibuya M.[48]                                |
|        |             |              | Vartanian A. et al.[49]                       |
|        |             |              | Frank N.Y. et al.[5]                          |
| Nodal  | tumor cells | -            | McAllister J.C. et al.[17]                    |
|        |             |              | Hendrix M.J. et al.[50]                       |
| Laminin| BM          | BM           | Seftor R.E. et al.[51]                        |
|        |             |              | Simon-Assmann P. et al.[52]                   |
| PAS    | BM          | BM           | Folberg R. et al.[47]                         |
|        |             |              | Maniotis A.J. et al.[6]                       |

BM= Basement membrane
## Table 2

### Human MCC samples and VM.

| Patient | Age  | Specimen type            | Chemotherapy | VM   | Survival  | T* | Stage* |
|---------|------|--------------------------|--------------|------|-----------|----|--------|
| 1       | 61   | Cutaneous primary        | None         | Focal| 2Y 1m DOD | T2 | IIIA   |
| 2       | ND   | LN metastasis            | None         | Focal| ND        | ND | ND     |
| 3       | 83   | LN metastasis            | None         | Focal| 1Y 10m DOD| T1 | IIIA   |
| 4       | 76   | LN metastasis            | None         | Absent| 8m DOD    | T4 | IIIB   |
| 5       | 77   | Cutaneous primary**      | None         | Absent| 1Y 7m A  | T4 | IIIB   |
| 5       | 77   | Cutaneous recurrence**   | Carbo + Eto  | Absent| 1Y 7m A  | T4 | IIIB   |
| 6       | 78   | Cutaneous recurrence     | Carbo + Eto  | Diffuse| 3Y 5m DOD| T1 | IIIA   |

* Survival time from date of initial diagnosis;

* American Joint Committee on Cancer (AJCC) Staging System, 7th Edition; T= Tumor staging; DOD= Died of the disease, A= Alive; Y= Year(s); m= Month(s); ND= No data; LN= Lymph node;

** same site; Carbo= Carboplatin; Eto= Etoposide.